Download PDF
Der Nuklearmediziner 2009; 32(2): 135-141
DOI: 10.1055/s-0028-1105929
Nicht-FDG-PET

© Georg Thieme Verlag KG Stuttgart · New York

O-(2-[18F]Fluorethyl)-L-Tyrosin (FET) in der Diagnostik von Hirntumoren

O-(2-[18F]Fluorethyl)-L-Tyrosine in the Diagnostics of Brain TumorsK.-J. Langen 1 , G. Stoffels 1
  • 1Institut für Neurowissenschaften und Biophysik – Medizin, Forschungszentrum Jülich
Further Information

Publication History

Publication Date:
22 June 2009 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Positronen-Emissions-Tomografie (PET) mit radioaktiv markierten Aminosäuren hat sich in zahlreichen Studien als sehr leistungsfähig erwiesen, um die Diagnostik von zerebralen Gliomen zu verbessern. Die Magnetresonanztomografie (MRT) ist als Verfahren der ersten Wahl zur Diagnostik von zerebralen Gliomen unumstritten, erlaubt jedoch in vielen Situationen nur eine eingeschränkte Differenzierung des Tumorgewebes von unspezifischen Gewebsveränderungen. Die Aminosäure O-(2-[18F]Fluorethyl)-L-Tyrosin (FET) ist ein neuer PET-Tracer, der wie [18F]-Fluordeoxyglukose (FDG) in großen Mengen hergestellt werden kann und damit für den breiten klinischen Einsatz geeignet ist. Die FET-PET bietet eine spezifischere Darstellung der Lokalisation und Ausdehnung des soliden Gliomgewebes als die MRT, was bei der Planung einer Biopsie, eines neurochirurgischen Eingriffs und einer Bestrahlung sehr hilfreich sein kann. Des Weiteren können Tumorrezidive von posttherapeutischen Veränderungen mit hoher Spezifität differenziert, wertvolle prognostische Informationen bei niedriggradigen Gliomen gewonnen und Therapieeffekte frühzeitig beurteilt werden.

Abstract

Positron emission tomography (PET) using radiolabeled amino acids has shown great potential for a more accurate diagnosis of cerebral gliomas. Magnetic resonance imaging (MRI) is the investigation of choice for diagnosing cerebral glioma, but its capacity to differentiate tumor tissue from non-specific tissue changes is limited. ([18F] Fluoroethyl)-L-tyrosine (FET) is a new tracer for PET that can be produced with high efficiency and distributed on a wide clinical scale like [18F]-Fluorodeoxyglucose (FDG). The use of FET PET allows better delineation of tumor margins and improves targeting of biopsy and radiotherapy, and planning surgery. In addition, amino acid imaging appears useful in distinguishing tumor recurrence from non-specific post-therapeutic scar tissue, predicting prognosis in low grade gliomas, and monitoring metabolic response during treatment.

Schlüsselwörter

Aminosäure-PET - Hirntumoren - O-(2-[18F]Fluorethyl)-L-Tyrosin (FET)

Key words

amino acid PET - brain tumors - O-(2-[18F]Fluorethyl)-L-tyrosine (FET)

Literatur

  • 1 Floeth FW, Pauleit D, Wittsack HJ. et al . Multimodal metabolic imaging of cerebral gliomas using positron emission tomography with [18F]-fluoroethyl-l-tyrosine and magnetic resonance spectroscopy.  J Neurosurgery. 2005;  102 318-327
    CrossrefPubMedGoogle Scholar
  • 2 Floeth FW, Pauleit D, Sabel M. et al . 18F-FET PET Differentiation of ring enhancing brain lesions.  J Nucl Med. 2006;  47 776-782
    PubMedGoogle Scholar
  • 3 Floeth FW, Pauleit D, Sabel M. et al . Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma.  J Nucl Med. 2007;  48 519-527
    CrossrefPubMedGoogle Scholar
  • 4 Floeth FW, Sabel M, Stoffels G. et al . Prognostic value of O-(2-[18F]fluoroethyl)-L-tyrosine PET and MRI in small unspecific incidental brain lesions with suspicion of low grade glioma.  J Nucl Med. 2008;  49 730-737
    CrossrefPubMedGoogle Scholar
  • 5 Grosu AL, Weber WA, Franz M. et al . Reirradiation of recurrent high-grade gliomas using amino acid PET(SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.  Int J Radiat Oncol Biol Phys. 2005;  63 511-519
    CrossrefPubMedGoogle Scholar
  • 6 Hamacher K, Coenen HH. Efficient routine production of the 18F-labelled amino acid O-(2-[18F]fluoroethyl)-L-tyrosine.  Appl Radiat Isot. 2002;  57 853-856
    CrossrefPubMedGoogle Scholar
  • 7 Heiss P, Mayer S, Herz M. et al . Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo.  J Nucl Med. 1999;  40 1367-1373
    PubMedGoogle Scholar
  • 8 Kaim AH, Weber B, Kurrer MO. et al . (18)F-FDG and (18)F-FET uptake in experimental soft tissue infection.  Eur J Nucl Med Mol Imaging. 2002;  29 648-654
    CrossrefPubMedGoogle Scholar
  • 9 Laïque S, Egrise D, Monclus M. et al . L-amino acid load to enhance PET differentiation between tumor and inflammation: an in vitro study on (18)F-FET uptake.  Contrast Media Mol Imaging. 2006;  1 212-220
    CrossrefPubMedGoogle Scholar
  • 10 Langen KJ, Pauleit D, Coenen HH. [123I]Iodo-α-Methyl-L-Tyrosine: uptake mechanisms and clinical applications.  Nucl Med Biol. 2002;  29 625-631
    CrossrefPubMedGoogle Scholar
  • 11 Langen KJ, Jarosch M, Muhlensiepen H. et al . Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas.  Nucl Med Biol. 2003;  30 501-508
    CrossrefPubMedGoogle Scholar
  • 12 Langen KJ, Hamacher K, Weckesser M. et al . O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications.  Nucl Med Biol. 2006;  33 287-294
    CrossrefPubMedGoogle Scholar
  • 13 Langen KJ, Stoffels G. Hirntumoren.  Nuklearmediziner. 2007;  30 204-211
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Langen KJ, Tatsch K, Grosu AL. et al . Diagnostik von zerebralen Gliomen mit radioaktiv markierten Aminosäuren.  Dtsch Arztebl. 2008;  105 55-61
    PubMedGoogle Scholar
  • 15 Mehrkens JH, Pöpperl G, Rachinger W. et al . The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment.  J Neurooncol. 2008;  88 27-35
    CrossrefPubMedGoogle Scholar
  • 16 Messing-Jünger AM, Floeth FW, Pauleit D. et al . Multimodal target point assessment for atereotactic biopsy in children with diffuse bithalamic astrocytomas.  Childs Nerv Syst. 2002;  18 445-449
    CrossrefPubMedGoogle Scholar
  • 17 Pauleit D, Floeth F, Herzog H. et al . Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine.  Eur J Nucl Med Mol Imaging. 2003;  30 519-524
    CrossrefPubMedGoogle Scholar
  • 18 Pauleit D, Floeth F, Tellmann L. et al . Comparison of O-(2-[18F]fluoro-ethyl)-L-tyrosine (FET) PET and 3-[123I]Iodo-α-Methyl-L-tyrosine (IMT) SPECT in brain tumors.  J Nucl Med. 2004;  45 374-381
    PubMedGoogle Scholar
  • 19 Pauleit D, Floeth F, Hamacher K. et al . O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with Magnetic Resonance Imaging Improves the Diagnostic Assessment of Cerebral Gliomas.  Brain. 2005;  128 678-687
    CrossrefPubMedGoogle Scholar
  • 20 Pauleit D, Stoffels G, Schaden W. et al . PET with O-(2-[18F]fluoroethyl)-L-tyrosine (FET) in peripheral tumors: First clinical Results.  J Nucl Med. 2005;  46 411-416
    PubMedGoogle Scholar
  • 21 Pauleit D, Zimmermann A, Stoffels G. et al . FET PET compared with FDG PET and CT in patients with head-neck cancers.  J Nucl Med. 2006;  47 256-261
    PubMedGoogle Scholar
  • 22 Pöpperl G, Gotz C, Rachinger W. et al . Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.  Eur J Nucl Med Mol Imaging. 2004;  31 1464-1470
    CrossrefPubMedGoogle Scholar
  • 23 Pöpperl G. PET (und PET/CT) – Stellenwert in der Diangostik von primären Hirntumore.  Nuklearmediziner. 2004;  27 246-254
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Pöpperl G, Goldbrunner R, Gildehaus FJ. et al . O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.  Eur J Nucl Med Mol Imaging. 2005;  32 1018-1025
    CrossrefPubMedGoogle Scholar
  • 25 Pöpperl G, Gotz C, Rachinger W. et al . Serial O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma.  Eur J Nucl Med Mol Imaging. 2006;  33 792-800
    CrossrefPubMedGoogle Scholar
  • 26 Pöpperl G, Kreth FW, Herms J. et al . Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?.  J Nucl Med. 2006;  47 393-403
    PubMedGoogle Scholar
  • 27 Pöpperl G, Kreth FW, Mehrkens JH. et al . FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading.  Eur J Nucl Med Mol Imaging. 2007;  34 1933-1942
    CrossrefPubMedGoogle Scholar
  • 28 Rachinger W, Goetz C, Pöpperl G. et al . Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas.  Neurosurgery. 2005;  57 505-511
    CrossrefPubMedGoogle Scholar
  • 29 Rau FC, Weber WA, Wester HJ. et al . O-(2-[18F]Fluoroethyl)-L-tyro-sine (FET): a tracer for differentiation of tumour from inflamma-tion in murine lymph nodes.  Eur J Nucl Med Mol Imaging. 2002;  29 1039-1046
    CrossrefPubMedGoogle Scholar
  • 30 Salber D, Stoffels G, Pauleit D. et al . Differential uptake of 18F-FET, 3H-L-methionine and 3H-deoxyglucose in brain abscesses.  J Nucl Med. 2007;  48 2056-2062
    CrossrefPubMedGoogle Scholar
  • 31 Salber D, Stoffels G, Pauleit D. et al . Differential uptake of 18F-FET and 3H-L-methionine in focal cortical ischemia.  Nucl Med Biol. 2006;  33 1029-1035
    CrossrefPubMedGoogle Scholar
  • 32 Spaeth N, Wyss MT, Weber B. et al . Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence.  J Nucl Med. 2004;  45 1931-1938
    PubMedGoogle Scholar
  • 33 Spaeth N, Wyss MT, Pahnke J. et al . Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L: -tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat.  Eur J Nucl Med Mol Imaging. 2006;  33 673-682
    CrossrefPubMedGoogle Scholar
  • 34 Stadlbauer A, Prante O, Nimsky C. et al . Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging.  J Nucl Med. 2008;  49 721-729
    CrossrefPubMedGoogle Scholar
  • 35 Stöber B, Tanase U, Herz M. et al . Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells.  Eur J Nucl Med Mol Imaging. 2006 Aug;  33 ((8)) 932-939
    CrossrefPubMedGoogle Scholar
  • 36 Stockhammer F, Plotkin M, Amthauer H. et al . Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas.  J Neurooncol.. 2008;  88 205-210
    CrossrefPubMedGoogle Scholar
  • 37 Vees H, Senthamizhchelvan S, Miralbell R. et al . Assessment of various strategies for (18)F-FET PET-guided delineation of target volumes in high-grade glioma patients.  Eur J Nucl Med Mol Imaging. 2008 Sep;  26 , [Epub ahead of print]
    PubMedGoogle Scholar
  • 38 Weber WA, Wester HJ, Grosu AL. et al . O-(2-[18F]Fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study.  Eur J Nucl Med. 2000;  27 542-549
    CrossrefPubMedGoogle Scholar
  • 39 Weckesser M, Langen KJ, Rickert CH. et al . Initial experiences with O-(2-[18F]fluorethyl)-L-tyrosine PET in the evaluation of primary brain tumors.  Eur J Nucl Med. 2005;  32 422-429
    CrossrefPubMedGoogle Scholar
  • 40 Wester HJ, Herz M, Weber W. et al . Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging.  J Nucl Med. 1999;  40 205-212
    PubMedGoogle Scholar
  • 41 Wyss MT, Hofer S, Hefti M. et al . Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake.  J Nucl Med. 2007;  48 1047-1052
    CrossrefPubMedGoogle Scholar

Korrespondenzadresse

Prof. Dr. K.-J. Langen

Institut für Neurowissenschaften und Biophysik – Medizin

Forschungszentrum Jülich

Leo-Brandt-Straße

52425 Jülich

Phone: +49/2461 61 59 00

Fax: +49/2461 61 82 61

Email: k.j.langen@fz-juelich.de

      >